Aetion, a NYC-based healthcare technology company that delivers the real-world analytics and evidence needed for value-based healthcare has raised $11.2 million in Series A funding led by Flare Capital Partners and joined by Lakestar. The company plans to utilize the funding to extend the capabilities of its real-world evidence platform, as well as expand and commercialize its solutions for the benefit of the healthcare ecosystem. The platform enables payers and providers to collaborate in real-time with biopharmaceutical and medical device companies to develop therapeutic insights and make smart choices in patient care.
Founded by Harvard Medical School faculty members and top big data technologists, the Aetion Evidence Platform™ generates the real-world evidence that empowers the healthcare industry to engage in a value-based business model. The platform combines best-of-breed science with leading-edge computing technology to unlock evidence from the everyday clinical and financial interactions of the healthcare system. Aetion customers can analyze virtually any real-world data to determine medical need, comparative effectiveness and the overall value profile of medical treatments and interventions.
“With the healthcare industry moving toward data-driven, value-based care, essential evidence is a necessity for assessing the expected and realized value of medical products and treatments,” stated Jeremy A. Rassen, Sc.D., co-founder, president and chief scientific officer, Aetion. “Our platform combines modern analytic methods with rapid-cycle computing technology to generate the transparent, real-time insights necessary for evaluating the outcomes and value of medical treatments and interventions.”
